



RECEIVED  
AUG 10 2001  
TECH CENTER 1600/2900

PATENT CASE IN01154K

1553  
1600

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
K. Chen *et al.* ) Examiner: Not assigned yet  
Serial No.: 09/825,399 ) Group Art Unit: Not assigned yet  
Filed: April 3, 2001 ) Atty. Docket No.: IN01154K

For: **Macrocyclic NS3-Serine Protease Inhibitors of Hepatitis C Virus Comprising N-Cyclic P2 Moieties**

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

It is requested that the following documents cited in the application, as listed below and in the accompanying form PTO-1449, be considered and made of record.

**Documents cited in the Application:**

U.S. 5,712,145  
WO 89/04669  
WO 98/17679  
WO 98/22496  
WO 99/07734  
WO 00/09558  
WO 00/09543  
EP 381 216

**Publications:**

Pizzi *et al.* (1994) *Proc. Natl. Acad. Sci (USA)* 91:888-892  
Failla *et al.* (1996) *Folding & Design* 1:35-42  
Kollykhalov *et al.* (1994) *J. Virol.* 68:7525-7533  
Komoda *et al.* (1994) *J. Virol.* 68:7351-7357  
Landro *et al.* (1997) *Biochem.* 36:9340-9348  
Ingallinella *et al.* (1998) *Biochem.* 37:8906-8914  
Llinàs-Brunet *et al.* (1998) *Bioorg. Med. Chem. Lett.* 8:1713-1718  
Martin *et al.* (1998) *Biochem.* 37:11459-11468  
Dimasi *et al.* (1997) *J. Virol.* 71:7461-7469  
Martin *et al.* (1997) *Protein Eng.* 10:607-614  
Elzouki *et al.* (1997) *J. Hepat.* 27:42-48  
*BioWorld Today* 9(217): 4 (November 10, 1998)  
Berenguer *et al.* (1998) *Proc. Assoc. Am. Physicians* 110(2):98-112  
Hoofnagle *et al.* (1997) *N. Engl. J. Med.* 336:347  
R. Zhang *et al.*, *Analytical Biochemistry*, 270 (1999) 268-275

F (7)



Sali *et al*, *Biochemistry*, 37 (1998) 3392-3401  
K. Barlos *et al*, *Int. J. Pept. Protein Res.*, 37 (1991), 513-520  
K. Holmber *et al*, *Acta Chem. Scand.*, B33 (1979) 410-412  
S. Agrawal *et al*, "Development and Characterization of Hepatitis C Virus Serine  
Protease Cell-based Trans-Cleavage Assay", *Hepatology* Supplement to Volume 30 (No. 4,  
Part 2, October 1999), *Abstract No. 615* (Proceedings of AASLD 50<sup>th</sup> Annual Meeting,  
Dallas, Texas, November 5-9, 1999).

The submission of these documents is not to be presumed as an admission that these documents are prior art. The documents are being furnished solely for their possible utility in the examination of the present case. Since no Office Action has issued on the merits of this case, Applicants believe that no fee is due at this time. If, however, any fees are due, the Office may charge such fees to Deposit Account No. 19-0365.

If the Examiner has any questions, the Examiner is invited to contact the undersigned.

August 6, 2001  
Schering-Plough Corporation  
2000 Galloping Hill Road  
Patent Department, K-6-1, 1990  
Kenilworth, NJ 07033  
Tel: (908) 298-5068  
Fax: (908) 298-5388

Respectfully submitted,

Palaiyur S. Kalyanaraman  
Attorney for Applicants  
Reg. No. 34,634

I hereby certify that this correspondence  
is being deposited with the U.S. Postal  
Service as First Class Mail in an envelope  
addressed to Assistant Commissioner for  
Patents, Washington, D.C. 20231 on

August 6, 2001

Palaiyur S. Kalyanaraman  
Registered Representative

  
8/6/2001  
Signature and Date of Signature



RECEIVED

AUG 10 2001

TELEPHONE CENTER 1600/2900

Sheet 1 of 1

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: IN01154K		SERIAL NO.: 09/825,399	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)				APPLICANT: CHEN, et al			
				FILING DATE: April 3, 2001		GROUP: To Be Assigned	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	5,712,145					
	AB						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AC	WO 89/04669					
	AD	WO 98/17679					
	AE	WO 98/22496					
	AF	WO 99/07734					
	AG	WO 00/09558					
	AH	WO 00/09543					
	AI	EP 381 216					
	AJ						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AK	Pizzi, (1994) <i>Proc. Natl. Acad. Sci(USA)</i> 91:888-892					
	AL	Failla (1996) <i>Folding &amp; Design</i> , 1:35-42					
	AM	Kollykhalov(1994) <i>J. Virol.</i> , 68:7525-7533					
	AN	Komoda(1994) <i>J. Virol.</i> 68:7351-7357					
	AO	Landro (1997) <i>Biochem.</i> 36:9340-9348					
	AP	Ingallinella (1998) <i>Biochem.</i> 37:8906-8914					
	AQ	Llinas-Brunet(1998) <i>Bioorg. Med. Chem. Lett.</i> 8:1713-1718					
	AR	Martin (1998) <i>Biochem.</i> 37:37:11459-11468					
	AS	Dimasi(1997) <i>J. Virol.</i> 71:7461-7469					
	AT	Martin(1997) <i>Protein Eng.</i> 10:607-614					
	AU	Elzouki(1997) <i>J. Hepat.</i> 27:42-48					
	AV	<i>BioWorld Today</i> 9(217): 4(November 10, 1998)					
	AW	Berenguer(1998) <i>Proc. Assoc. Am. Physicians</i> ,110(2):98-112					
	AX	Hoofnagle(1997) <i>New England Journal of Medicine</i> 336:347					
	AY	Zhang (1999) <i>Analytical Biochemistry</i> 270:268-275					
	AZ	Sali(1998) <i>Biochemistry</i> 37:3392-3401					
	BA	Barlos (1991) <i>Int. J. Pept. Protein Res.</i> 37:513-520					
	BB	Holmberg(1979) <i>Acta Chem. Scand</i> B33:410-412					
	BC	Agrawal(1999) <i>Hepatology</i> Supplement to Vol. 30"Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay"					
	BD	Hughes (1992) <i>Org. Reactions</i> 42:335					
	BE	Heck (1989) <i>Org. Reactions</i> 27:345-390					

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	